Galvokimig clinical trials
Also written UCB9741.
How each study uses galvokimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the galvokimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test galvokimig.
Studies
Open first, then newest update. How each study uses galvokimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis BronchiectasisRecruitingPhase 2UCB Biopharma SRLNCT07720375Written as Galvokimig
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisRecruitingPhase 2UCB Biopharma SRLNCT07725939Written as Galvokimig
- A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisActive, not recruitingPhase 2UCB Biopharma SRLNCT07277660Written as Galvokimig
- A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic DermatitisCompletedPhase 1/2UCB Biopharma SRLNCT04643457Written as UCB9741
- A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese ParticipantsCompletedPhase 1UCB Biopharma SRLNCT06315335Written as UCB9741
Codes
What other systems call galvokimig · ClinicalTrials.gg INT015598
- UNII (FDA) 85A4592PC8GALVOKIMIGOne source FDA
- NCI Thesaurus C203147GalvokimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 85A4592PC8 | GALVOKIMIG | One source FDA |
| NCI Thesaurus | C203147 | Galvokimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.